Ultramicronized Palmitoylethanolamide in the Management of Neuropathic Pain Related to Chronic Inflammatory Demyelinating Polyneuropathy: A Proof-of-Concept Study
Open-label, no control groupHumans
- Design
- Open-label, no control group
- Subjects
- 14 patients at one centre. All completed.
- Dose used in the study
- 600 mg of ultramicronised palmitoylethanolamide twice a day (Normast 600 tablets)
- Duration
- 60 days of treatment within 180 days of observation
- What was measured
- Pain intensity, the Neuropathic Pain Symptoms Inventory and a quality of life questionnaire
What the authors reported
Pain intensity (p = 0.0015), neuropathic pain symptoms (p = 0.0007) and quality of life (p = 0.0036) improved during treatment. No adverse events related to the supplement were observed.
Limits of this study
An open-label study with no placebo, 14 patients and one centre. The authors name these limits themselves. The study received no external funding.
Source
PubMed 38792328 · doi:10.3390/jcm13102787
Entry checked against the full text at the publisher (MDPI) on 2026-09-21. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.